Additional file 1: of Safety and antitumor activity of the antiâPD-1 antibody pembrolizumab in patients with advanced, PD-L1âpositive papillary or follicular thyroid cancer

Mehnert, Janice; Varga, Andrea; Brose, Marcia S.; Aggarwal, Rahul; Lin, Chia-Chi; Prawira, Amy; Braud, Filippo; Tamura, Kenji; Doi, Toshihiko; A. Piha-Paul, Sarina; Gilbert, Jill; Saraf, Sanatan; Thanigaimani, Pradeep; Cheng, Jonathan; Keam, Bhumsuk

doi:10.6084/m9.figshare.7802801.v1

12885_2019_5380_MOESM1_ESM.pdf (118.79 kB)

Additional file 1: of Safety and antitumor activity of the antiâPD-1 antibody pembrolizumab in patients with advanced, PD-L1âpositive papillary or follicular thyroid cancer

journal contribution

posted on 2019-03-04, 05:00 authored by Janice Mehnert, Andrea Varga, Marcia S. Brose, Rahul Aggarwal, Chia-Chi Lin, Amy Prawira, Filippo Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha-Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan Cheng, Bhumsuk Keam

Table S1. Institutional Review Board or Ethics Committee of Each Participating Site. Description of data: Provides details of institutional review board/ethics committees for each participating site. (PDF 118 kb)

Funding

Merck & Co., Inc., Kenilworth, NJ, USA

History

Usage metrics

Keywords

Thyroid cancer Immunotherapy Pembrolizumab AntiâPD-1 PD-1 PD-L1

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC